"ACT Venture Partners is excited to announce its investment in Meddenovo, a startup transforming drug design through AI, advanced molecular modeling, and a focus on cyclic peptides. This investment will empower Meddenovo to accelerate the development of its AI-driven platform and expand its cutting-edge solutions for pharmaceutical companies, enabling faster and more efficient drug discovery."
The Challenge: Unlocking the Potential of Cyclic Peptides in Drug Discovery
Drug discovery, particularly for complex diseases such as cancer and autoimmune disorders, remains a lengthy, costly, and high-risk process. Traditional methods, which rely on synthesizing and testing numerous compounds, are resource-intensive and often miss promising candidates due to time and financial constraints.
Cyclic peptides (CPs), a groundbreaking advancement in pharmaceutical science, offer a powerful alternative. Combining the strengths of small molecules and antibodies, cyclic peptides exhibit high binding affinities and stability, making them particularly potent for disrupting complex protein interactions. However, despite their promise, cyclic peptides remain underutilized because current drug development solutions focus primarily on small molecules, and there is no AI-based prediction tool tailored for cyclic peptides due to insufficient experimental data.
Meddenovo: Revolutionizing Drug Design with AI and Cyclic Peptides
Meddenovo addresses these challenges by using AI and molecular modelling to create an innovative platform specifically designed for cyclic peptides. “Our platform is the only one specifically designed to harness the potential of cyclic peptides,” said Dr. Ilke Ugur Marion, Co-founder & CEO. “Despite their ideal pharmaceutical properties, cyclic peptides remain an untapped resource in drug development. Meddenovo’s mission is to fill this gap using AI-powered technology to streamline the design and testing of new therapeutics.”
Dr. Antoine Marion, Co-founder & CTO, added, “We are committed to advancing drug design and making a significant impact on the pharmaceutical industry. Our goal is to reduce the time it takes to bring new drugs to market, ultimately accelerating the development of therapies for diseases such as cancer, autoimmune disorders, and global health concerns like antimicrobial resistance.”
Unlike traditional methods, Meddenovo produces its own data through proprietary computer-based simulation tools. These tools allow the company to develop AI models that can predict and optimize cyclic peptides as drug candidates, speeding up research and enabling faster discovery of new therapies compared to current methodologies.
Founders Leading the Innovation
The founders of Meddenovo, Dr. Ilke Ugur Marion and Dr. Antoine Marion, bring extensive expertise and passion to the company's mission. Dr. Ilke Ugur Marion, Co-founder & CEO, has a robust background in drug development, scientific research, and project management. Dr. Antoine Marion, Co-founder & CTO, is an expert in developing computational chemistry codes, contributing deep knowledge in design method development. Together, they lead a dedicated team committed to advancing drug design.
Market Opportunities and Growth Potential
As Gokhan Guner, Managing Partner at ACT Venture Partners, noted: “Meddenovo targets an emerging area in drug design that holds immense potential for growth. Their innovative approach to leveraging AI for cyclic peptides not only addresses industry challenges but also opens new opportunities for creating life-saving therapies.”
The global market for therapeutic peptides is vast and growing. Meddenovo targets pharmaceutical and biotech companies looking to enhance their drug discovery processes. By offering AI-powered platforms designed to reduce the time and cost of discovering new drugs, Meddenovo is well-positioned to capitalize on the increasing demand for innovative therapeutic solutions. This focus on cyclic peptides, combined with Meddenovo’s scalable software solutions, provides a strong foundation for sustained growth and market leadership in the pharmaceutical sector.
What’s Next for Meddenovo?
The investment from ACT Venture Partners will be instrumental in accelerating Meddenovo’s research and development, enhancing its AI-driven platforms, and expanding its customer base and partnerships. This includes transitioning from a service-based model to a Software as a Service (SaaS) model, as well as fostering co-development opportunities with key players in the pharmaceutical industry.
Looking ahead, Meddenovo plans to continue expanding its team and forging new partnerships to drive its mission forward. The company remains committed to revolutionizing drug design by making cutting-edge advancements in AI and cyclic peptide technology. With the support of ACT Venture Partners, Meddenovo is poised to make a significant impact on the future of healthcare by streamlining the development of effective, life-saving therapies.
Stay tuned about Meddenovo:
